Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability

BACKGROUND: Chimeric antigen receptor-engineered T cell (CAR-T) therapy has shown promising potential for anti-cancer treatment. However, for pancreatic ductal adenocarcinoma (PDAC), the lack of infiltrative ability of these CAR-T cells leads to sub-optimal treatment outcome. METHODS: Chemokine (C-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jian-fei, Wang, Zu-wei, Liao, Cheng-yu, Chen, Zhi-wen, Kang, Feng-ping, Lin, Cai-feng, Lin, Tian-sheng, Huang, Long, Tian, Yi-feng, Chen, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391072/
https://www.ncbi.nlm.nih.gov/pubmed/35990619
http://dx.doi.org/10.3389/fimmu.2022.958960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391072/
https://www.ncbi.nlm.nih.gov/pubmed/35990619
http://dx.doi.org/10.3389/fimmu.2022.958960

Ejemplares similares